We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Show more
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 3.19 | 3.42 | 3.0703 | 743740 | 3.23524372 | CS |
4 | -0.1888 | -5.58778264473 | 3.3788 | 3.77 | 3.0703 | 997480 | 3.43310454 | CS |
12 | -0.28 | -8.06916426513 | 3.47 | 4.5 | 2.98 | 1428226 | 3.5893591 | CS |
26 | 0.52 | 19.4756554307 | 2.67 | 4.5 | 2.06 | 892036 | 3.29273933 | CS |
52 | 1.26 | 65.2849740933 | 1.93 | 4.5 | 1.38 | 671572 | 2.83800301 | CS |
156 | -23.302 | -87.9586290201 | 26.492 | 29 | 1.3 | 575153 | 8.13321912 | CS |
260 | -15.41 | -82.8494623656 | 18.6 | 53.762 | 1.3 | 696864 | 19.28549989 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions